Breakthrough Pain clinical trials
The registry lists 60 studies for Breakthrough Pain across more than 10 countries. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-18.
Status
- Completed
- 37
- Terminated
- 9
- Recruiting
- 5
- Withdrawn
- 4
- Active, not recruiting
- 3
- Not yet recruiting
- 1
Phase
- Phase 3
- 22
- Phase 2
- 10
- Phase 4
- 10
- Phase 1
- 4
Where
- United States
- 26
- Spain
- 6
- Denmark
- 3
- Italy
- 2
- Puerto Rico
- 2
- China
- 2
Who runs them
Cephalon (11) · Kyowa Kirin Co., Ltd. (4) · Angelini Farmacéutica (3) · Nycomed (3) · AHS Cancer Control Alberta (2) · Nanfang Hospital, Southern Medical University (2) · Columbia University (2) · BioDelivery Sciences International (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 60 — search for more.
- Failing Epidural Analgesia During LaborRecruitingNCT074736091 country
- Programmed Intermittent Epidural Bolus Compared With Continuous Infusion in Multiparous WomenRecruitingNCT06580327Not applicable1 country
- PIEB Compared With CEI on Breakthrough Pain in Nulliparous WomenRecruitingNCT06494280Not applicable1 country
- Paediatric Breakthrough Pain AssessmentNot yet recruitingNCT06790719
- A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT063083281 country
- A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal MucositisRecruitingNCT062877881 country
- Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During LabourActive, not recruitingNCT04011150Phase 31 country
- Comparison of Regimens MPIB, CIPCEA, PCEAActive, not recruitingNCT02278601Phase 31 country
- Dexamethasone-Enhanced TAP Block in LapcholeActive, not recruitingNCT07182110Phase 11 country
- Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer PatientsCompletedNCT00263575Phase 31 country
- Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid RequirementWithdrawnNCT05053308Not applicable
- A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After ColectomyStatus unknownNCT05200806Phase 41 country
- Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough PainCompletedNCT05037539Phase 1/21 country
- Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back PainCompletedNCT02886286Phase 41 country
- Sublingual Fentanyl for the Management of Breakthrough PainTerminatedNCT02514252Phase 21 country
- A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer PatientsCompletedNCT00684632Phase 31 country
- Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer PatientsWithdrawnNCT03809455Phase 2
- Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)CompletedNCT034351201 country
- Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer SubjectsCompletedNCT00293033Phase 31 country
- Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in OutpatientsTerminatedNCT00351715Phase 21 country
- Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional GastrostomyCompletedNCT02869321Phase 41 country
- Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain OutpatientsTerminatedNCT02591017Phase 31 country
- Comparison of Epidural Fentanyl and Clonidine for Breakthrough PainCompletedNCT01846221Phase 41 country
- Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative IntentCompletedNCT028363791 country
- Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care UnitsCompletedNCT028405001 country
- An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.WithdrawnNCT01839552Phase 41 country
- Sublingual Methadone for the Management of Cancer Breakthrough PainCompletedNCT00125294Phase 1
- The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee OsteoarthritisCompletedNCT01383954Phase 41 country
- Staccato Fentanyl Single and Multidose PKCompletedNCT00402350Phase 11 country
- A Comparative Study of KW-2246CompletedNCT01326689Phase 31 country
- Procedural Pain in Palliative Care: Prevalence, Intensity and TreatmentCompletedNCT024379291 country
- Oral Piroxicam Versus Buccal Fentanyl in Breakthrough PainCompletedNCT02382653Not applicable
- Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal MucositisCompletedNCT020505031 country
- A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough PainCompletedNCT00833040Phase 21 country
- An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.TerminatedNCT019017181 country
- Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough PainCompletedNCT00236093Phase 23 countries
- Treatment of Breakthrough Pain in Opioid Tolerant Cancer PatientsCompletedNCT00105287Phase 31 country
- Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough PainCompletedNCT00214942Phase 31 country
- Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough PainCompletedNCT00214955Phase 31 country
- Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)CompletedNCT00236041Phase 22 countries
- An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With CancerCompletedNCT01006356Phase 4
- Inhaled Morphine Compared With Morphine By Mouth in Treating Cancer Patients With Breakthrough PainCompletedNCT00020618Phase 21 country
- Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With CancerCompletedNCT01842893Phase 31 country
- Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough PainCompletedNCT00236145Phase 3
- Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough PainTerminatedNCT00387010Phase 31 country
- Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid TherapyCompletedNCT00293020Phase 31 country
- Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant PatientsTerminatedNCT00842829Phase 47 countries
- Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 YearsCompletedNCT009947601 country
- OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer PatientsCompletedNCT00105937Phase 31 country
- Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant PainTerminatedNCT00278824Phase 21 country